List of Figures

Figure 1: Milestone of OVTs Development
Figure 2: OVs as Cancer Therapy
Figure 3: The combination of OVTs with Other Therapeutic Approaches
Figure 4: The Multiple Modes of Action of an OV
Figure 5: Virus Targeting Tumor Cells in Various Ways
Figure 6: Mechanism of Anticancer Activity of OVs
Figure 7: Global Heat Map of all cancers in 2020, both sexes, all ages
Figure 8: Total incident cases of selected cancer types across the 7MM (2019–2032)
Figure 9: Target patient Pool of OVTs by Cancer Types across the 7MM (2019–2032)
Figure 10: Treated cases by Cancer Types across the 7MM (2019–2032)
Figure 11: Total Incident cases of selected cancer types across the US (2019–2032)
Figure 12: Target patient Pool of OVTs by Cancer Types across the US (2019–2032)
Figure 13: Treated cases by Cancer Types in the US (2019–2032)
Figure 14: Total Incident cases of selected cancer types in EU5 (2019–2032)
Figure 15: Target patient Pool of OVTs by Cancer Types across EU5 (2019–2032)
Figure 16: Treated cases by Cancer Types across EU5 (2019–2032)
Figure 17: Total Incident cases of selected cancer types in Japan (2019–2032)
Figure 18: Indication wise target patient pool across Japan (2019–2032)
Figure 19: Treated cases by Cancer Types across Japan (2019–2032)
Figure 20: Structure of DNX-2401 (tasadenoturev)
Figure 21: Mode of Action of Pexa-Vec
Figure 22: Market Size of OVTs in the 7MM, USD Million (2019–2032)
Figure 23: Market Size of OVTs By Indications in the 7MM, USD Million (2019–2032)
Figure 24: 7MM Market Size of Oncolytic Virus Therapies in USD Million (2019–2032)
Figure 25: Market Size of OVTs in the US, USD Million (2019–2032)
Figure 26: Market Size of OVTs By Indications in the US, USD Million (2019–2032)
Figure 27: US Market Size of OVTs in USD Million (2019–2032)
Figure 28: Market Size of OVTs in EU5, USD Million (2019–2032)
Figure 29: Market Size of OVTs By Indications in the EU5, USD Million (2019–2032)
Figure 30: EU5 Therapywise market size of OVTs in USD Million (2019–2032)
Figure 31: Market Size of OVTs in Japan, USD Million (2019–2032)
Figure 32: Market Size of OVTs By Indications in Japan, USD Million (2019–2032)
Figure 33: Japan Market Size of OVTs in USD Million (2019–2032)

List of Tables

Table 1: Summary of OVTs
Table 2: Use of OVs for Cancer Diagnosis
Table 3: Administration Routes of OVs in Multiple Tumors
Table 4: Comparison Between Different Administration Methods
Table 5: Incident cases (2020) and Year-over-year (YOY) cancer growth rates
Table 6: Total incident cases of selected cancer types across the 7MM (in Thousands) (2019–2032)
Table 7: Target patient Pool of OVTs by Cancer Types across the 7MM (in Thousands) (2019–2032)
Table 8: Treated cases by Cancer Types across the 7MM (in Thousands) (2019–2032)
Table 9: Total Incident cases of selected cancer types across the US (in Thousands) (2019–2032)
Table 10: Target patient Pool of OVTs by Cancer Types across the US (in Thousands) (2019–2032)
Table 11: Treated cases by Cancer Types across the US (in Thousands) (2019–2032)
Table 12: Total Incident cases of selected cancer types across EU5 (in Thousands) (2019–2032)
Table 13: Total Target patient Pool of OVTs by Cancer Types across EU5 (in Thousands) (2019–2032)
Table 14: Treated cases by Cancer Types across EU5 (in Thousands) (2019–2032)
Table 15: Total Incident cases of selected cancer types in Japan (in Thousands) (2019–2032)
Table 16: Target patient Pool of OVTs by Cancer Types in Japan (in Thousands) (2019–2032)
Table 17: Treated cases by Cancer Types in Japan (in Thousands) (2019–2032)
Table 18: Summary of Results for the ITT Population From IMLYGIC Study 005/05
Table 19: IMLYGIC , Clinical Trial Description, 2022
Table 20: Results on Tumor Reduction Effect and Safety
Table 21: Comparison of emerging drugs under development
Table 22: ONCOS-102; Clinical Trial Description, 2022
Table 23: RP1; Clinical Trial Description, 2022
Table 24: Olvi-Vec; Clinical Trial Description, 2022
Table 25: DNX-2401; Clinical Trial Description, 2022
Table 26: Pexa-Vec (pexastimogene devacirepvec; JX-594), Clinical Trial Description, 2022
Table 27: G207; Clinical Trial Description, 2022
Table 28: LOAd703, Clinical Trial Description, 2022
Table 29: PVSRIPO; Clinical Trial Description, 2022
Table 30: 7MM Market Size of OVTs in USD Million (2019–2032)
Table 31: 7MM Market Size of OVTs By Indications in USD Million (2019–2032)
Table 32: 7MM Market Size of OVTs in USD Million (2019–2032)
Table 33: US Market Size of OVTs in USD Million (2019–2032)
Table 34: US Market Size of OVTs By Indications in USD Million (2019–2032)
Table 35: US Market Size of OVTs in USD Million (2019–2032)
Table 36: EU5 Market Size of OVTs in USD Million (2019–2032)
Table 37: EU5 Market Size of OVTs By Indications in USD Million (2019–2032)
Table 38: EU-5 Market Size of OVTs by Therapies in USD Million (2018–2032)
Table 39: Japan Market Size of OVTs in USD Million (2019–2032)
Table 40: Japan Market Size of OVTs By Indications in USD Million (2019–2032)
Table 41: Japan Market Size of OVTs in USD Million (2019–2032)
Table 42: NICE Assessment for OVT